On March 21, 2022, ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. (hereinafter referred to as "ImmuneOnco") declared the appointment of Dr. Lu Qiying was appointed as the chief medical officer and senior vice president of our Company in March 2022, and is responsible for formulating the clinical strategy and direct clinical development of our Group.

Dr. Lu has around 20 years of work experience as a physician and in development of oncology medicine. Prior to joining our Company, Dr. Lu served as a resident physician at the medical oncology department of Beijing Cancer Hospital from January 2003 to August 2005. He also served as a senior medical advisor at Merck Serono (Beijing) Pharmaceutical Research and Development Co., Ltd. Shanghai Office. Dr. Lu served as a clinical research physician at the medical department of Glaxosmithkline (China) R&D Company Limited. He also served as an associate director and clinician at Pfizer (China) Research and Development Co., Ltd., a Chinese subsidiary of Pfizer Inc., which is a multinational pharmaceutical company listed on the NYSE (stock code: PEF). Dr. Lu served as an associate director and oncology physician at AstraZeneca Investment (China) Company Limited, a Chinese subsidiary of AstraZeneca Plc, which is a company dually listed on the NASDAQ Global Market (stock code: AZN) and the London Stock Exchange (stock code: AZN). He served as a vice general manager of clinical development at Ascentage Pharma (Suzhou) Co., Ltd., a subsidiary of Ascentage Pharma Group International which is a company listed on the Stock Exchange (stock code: 6855). Dr. Lu also served at QureBio Biotech (Shanghai) Co., Ltd..

Dr. Lu obtained a master’s degree in immunology from Hebei Medical University in the PRC in June 2008.

Dr. Tian, Wenzhi, founder, chairman and CEO of ImmuneOnco, said:

"I am very happy and sincerely welcome Mr. Lu, Qiying to join the ImmuneOnco team. I believe that, with his extensive experience in the clinical development of therapy products for cancers, he will definitely be able to help the company develop rapidly in terms of clinical research and IND application.’  ‘ImmuneOnco are accelerating the realization of the great vision of 'developing first-class new drugs for the benefit of cancer patients'."

"We will work with all colleagues to build the company into a world-renowned biopharmaceutical company and develop first-class new anti-cancer drugs for cancer patients around the world."